No art

10/523,286 YONG CHU 4-21-2006

$%^STN;HighlightOn=;**HighlightOff=**;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:55:36 ON 21 APR 2006

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:55:44 ON 21 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 APR 2006 HIGHEST RN 881169-11-5
DICTIONARY FILE UPDATES: 19 APR 2006 HIGHEST RN 881169-11-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10523286\10523286.str





chain nodes :
10 11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-10 8-16 10-11 10-12 10-13 11-14 11-15 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-7 5-6 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 7-10 8-9 10-11 10-12 10-13 11-14 11-15 16-17
exact bonds :
8-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:56:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:56:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 96 TO ITERATE

100.0% PROCESSED 96 ITERATIONS 29 ANSWERS
SEARCH TIME: 00.00.01

L3 29 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 14:56:27 ON 21 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 20 Apr 2006 (20060420/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d ibib abs hitstr tot

Current application

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:142899 CAPLUS
DOCUMENT NUMBER: 140:181323
TITLE: Preparation of indolesulfonamides as tyrosine kinase inhibitors, in particular insulin-like growth factor 1 receptor (IGF-1R) inhibitors
INVENTOR(S): Dinsmore, Christopher J.; Beshore, Douglas C.; Bergman, Jeffrey M.; Lindsley, Craig W.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014300	A2	20040219	WO 2003-US24393	20030805
WO 2004014300	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493575	AA	20040219	CA 2003-2493575	20030805
EP 1534268	A2	20050601	EP 2003-784904	20030805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504668	T2	20060209	JP 2004-527739	20030805
PRIORITY APPLN. INFO.:			US 2002-402482P P	20020809
			WO 2003-US24393 W	20030805

OTHER SOURCE(S): CASREACT 140:181323; MARPAT 140:181323
GI



I



II

AB Title compds. I [wherein R1a, R1b = independently H, OH and derivs., NH2 and derivs., (un)substituted cyclo/alkyl, aryl, heterocyclyl; R2 = H, OH and derivs., NH2 and derivs., (un)substituted cyclo/alkyl, aryl; R3 = H, halo, (CH2)pOH and derivs., CO2H and derivs., CH:CH2 and derivs., NO2, (CH2)pNH2 and derivs., NHCHO and derivs., NHS(O)oR4, S(O)oR4, S(O)oNH2 and derivs., CN, (CH2)pNH(CH2)pH and derivs., etc.; R4 = (un)substituted cyclo/alkyl, aryl, heterocyclyl; m = 0-6; n = 0-6; q = 0-4; p = 0-6; o = 0-2; and their pharmaceutically acceptable salts, hydrates and stereoisomers] were prepared for inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. For example, I was prepared in 5 steps via substitution of benzenesulfonyl chloride with Et 5-chloro-1H-indole-2-carboxylate, sulfonation with concentrated H2SO4 in DCM, chlorination with oxalyl chloride in the presence of DCM/DMF, substitution with methylamine hydrochloride in the presence of TEA/DCM, and one-pot amidation with NH3/phenylsulfonyl group deprotection in i-PrOH. I inhibited insulin-like growth factor 1 receptor (IGF-1R) or Insulin receptor kinase with an IC50 ≤ 100 μM. Thus, I and their formulations are useful for treating cancer, diabetes, an autoimmune disorder, a hyperproliferative disorder, aging, acromegaly, and Crohn's disease.

IT **660412-51-1P**, 5-Bromo-3-[[N-(methyl)-N-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]amino]sulfonyl]-1H-indole-2-carboxamide **660412-56-6P**, 3-[(Dimethylamino)sulfonyl]-5-methoxy-1H-indole-2-carboxamide **660412-67-9P**, 5-Chloro-3-[[ethyl(methyl)amino]sulfonyl]-1H-indole-2-carboxamide **660412-68-0P**, 5-Chloro-3-[(diethylamino)sulfonyl]-1H-indole-2-carboxamide **660412-97-5P**, 5-Chloro-3-[(dimethylamino)sulfonyl]-1H-indole-2-carboxamide **660413-01-4P**, 5-Chloro-3-[[(2-methoxyethyl)(methyl)amino]sulfonyl]-1H-indole-2-carboxamide **660413-03-6P** **660413-05-8P** **660413-08-1P**, 5-Bromo-3-[[methyl[2-(1H-1,2,4-triazol-1-yl)ethyl]amino]sulfonyl]-1H-

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

indole-2-carboxamide **660413-10-5P**, 5-Bromo-3-[[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl]-1H-indole-2-carboxamide **660413-12-7P**, 5-Chloro-3-[[isopropyl(2-methoxyethyl)amino]sulfonyl]-1H-indole-2-carboxamide **660413-13-8P**, 3-[[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl]-5-hydroxy-1H-indole-2-carboxamide **660413-16-1P**, 3-[[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl]-5-methoxy-1H-indole-2-carboxamide **660413-18-3P**, 5-Chloro-3-[[(2,3-dihydroxypropyl)(methyl)amino]sulfonyl]-1H-indole-2-carboxamide **660413-19-4P**, 5-Chloro-3-[[(2-hydroxyethyl)(methyl)amino]sulfonyl]-1H-indole-2-carboxamide **660413-20-7P**, N-[[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl]-N-methylglycine **660413-21-8P**, N-[[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl]-N-methylglycinamide **660413-38-7P**, 5-Fluoro-3-[[[2-[[(4-methoxyphenyl)sulfonyl]amino]ethyl](methyl)amino]sulfonyl]-1H-indole-2-carboxamide **660414-04-0P**, 5-Chloro-3-[[methyl(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl]-1H-indole-2-carboxamide **660414-05-1P**, 5-Bromo-3-[[methyl(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl]-1H-indole-2-carboxamide **660414-06-2P**, 5-Iodo-3-[[methyl(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl]-1H-indole-2-carboxamide **660414-11-9P**, 5-Chloro-3-[[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl]-1H-indole-2-carboxamide **660414-19-7P**, 5-Chloro-3-[[methyl[(1-methylpiperidin-3-yl)methyl]amino]sulfonyl]-1H-indole-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IGF-1R inhibitor; prepn. of indolesulfonamides as tyrosine kinase inhibitors)

RN 660412-51-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-bromo-3-[[[(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl]methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660412-56-6 CAPLUS
CN 1H-Indole-2-carboxamide, 3-[(dimethylamino)sulfonyl]-5-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 660412-67-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[(ethylmethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 660412-68-0 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[(diethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 660412-97-5 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[(dimethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 660413-01-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[[(2-methoxyethyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660413-03-6 CAPLUS
CN 1H-Indole-2-carboxamide, 5-bromo-3-[[methyl[3-(methylamino)-1-oxopropyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660413-05-8 CAPLUS
CN β-Alanine, N-[[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 660413-08-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-bromo-3-[[methyl[2-(1H-1,2,4-triazol-1-yl)ethyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660413-10-5 CAPLUS
CN 1H-Indole-2-carboxamide, 5-bromo-3-[[(1,4-dioxan-2-ylmethyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660413-12-7 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[[(2-methoxyethyl)(1-methylethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660413-13-8 CAPLUS
CN 1H-Indole-2-carboxamide, 3-[[(2-bromoethyl)(2-hydroxyethyl)amino]sulfonyl]-5-hydroxy- (9CI) (CA INDEX NAME)



RN 660413-16-1 CAPLUS
CN 1H-Indole-2-carboxamide, 3-[[(2-bromoethyl)(2-hydroxyethyl)amino]sulfonyl]-5-methoxy- (9CI) (CA INDEX NAME)



RN 660413-18-3 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[[(2,3-dihydroxypropyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660413-19-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[[(2-hydroxyethyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660413-20-7 CAPLUS
CN Glycine, N-[[2-(aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 660413-21-8 CAPLUS
CN 1H-Indole-2-carboxamide, 3-[[(2-amino-2-oxoethyl)methylamino]sulfonyl]-5-chloro- (9CI) (CA INDEX NAME)



RN 660413-38-7 CAPLUS
CN 1H-Indole-2-carboxamide, 5-fluoro-3-[[[2-[[(4-methoxyphenyl)sulfonyl]amino]ethyl]methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660414-04-0 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[[methyl[(tetrahydro-2H-pyran-2-yl)methyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660414-05-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-bromo-3-[[methyl[(tetrahydro-2H-pyran-2-yl)methyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



IT 660413-42-3P, Ethyl 5-fluoro-3-[[[2-[[(4-methoxyphenyl)sulfonyl]amino]ethyl](methyl)amino]sulfonyl]-1-(phenylsulfonyl)-1H-indole-2-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indolesulfonamides as tyrosine kinase inhibitors)
RN 660413-42-3 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-fluoro-3-[[[2-[[(4-methoxyphenyl)sulfonyl]amino]ethyl]methylamino]sulfonyl]-1-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)





RN 660414-06-2 CAPLUS
CN 1H-Indole-2-carboxamide, 5-iodo-3-[[methyl[(tetrahydro-2H-pyran-2-yl)methyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660414-11-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[[(1,4-dioxan-2-ylmethyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 660414-19-7 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-3-[[methyl[(1-methyl-3-piperidinyl)methyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2000:553556 CAPLUS
DOCUMENT NUMBER: 133:150463
TITLE: Preparation of 3-substituted indole-2-carboxylic acids
for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis
INVENTOR(S): Faull, Alan Wellington; Kettle, Jason
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046199	A2	20000810	WO 2000-GB284	20000131
WO 2000046199	A3	20001130		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355734	AA	20000810	CA 2000-2355734	20000131
BR 2000008015	A	20011106	BR 2000-8015	20000131
EP 1173421	A2	20020123	EP 2000-901747	20000131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536362	T2	20021029	JP 2000-597270	20000131
ZA 2001005017	A	20020919	ZA 2001-5017	20010619
NO 2001003768	A	20011001	NO 2001-3768	20010801
US 6833387	B1	20041221	US 2001-889516	20011002

PRIORITY APPLN. INFO.: GB 1999-2455 A 19990205
WO 2000-GB284 W 20000131

OTHER SOURCE(S): MARPAT 133:150463
GI

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; X = CH2, SO2; R1 = (un)substituted aryl, heteroaryl; R2 = CO2H, CN, COCH2OH, etc.; R3 = OR15 (wherein R15 = substituted alkyl or cycloalkyl, (un)substituted heteroaryl), S(O)qR15 (q = 0-2), (CH2)sCO2H (s = 0-4), etc.; R4-R7 = H, (un)substituted hydrocarbyl, heterocyclyl, etc.] and their pharmaceutically acceptable salts, amides or esters, useful in the preparation of a medicament for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis, were prepared and formulated. Thus, hydrolysis of the corresponding ester afforded 93% II which showed IC50 of 6.86 μM against hMCP-1 receptor binding.

IT 287725-37-5P 287725-41-1P 287725-47-7P
287725-49-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-substituted indole-2-carboxylic acids for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis)

RN 287725-37-5 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-[[bis(2-hydroxyethyl)amino]sulfonyl]-1-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 287725-41-1 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[(3-

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1964:23245 CAPLUS
DOCUMENT NUMBER: 60:23245
ORIGINAL REFERENCE NO.: 60:4088h,4089a-c
TITLE: Reaction of indole derivatives with thionyl and sulfuryl chlorides
AUTHOR(S): Szmuszkovicz, Jacob
CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI
SOURCE: Journal of Organic Chemistry (1964), 29(1), 178-84
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 60:23245

GI For diagram(s), see printed CA Issue.

AB Reaction of 1-methylindole-2-carboxylic acid, the corresponding methyl ester (I), and of Et indole-2-carboxylate with thionyl chloride afforded sulfinyl chlorides (II, III, and IV, resp.). Thionyl chloride and N,1-dimethylindole-2-carboxamide led to sulfide (V, R = CONHMe) and imide sulfoxide (VI). III was converted to several sulfinamides (VII) on treatment with amines. VII were oxidized with permanganate to sulfonamides (VIII). Treatment of III with hydrazine in the cold gave disulfide (IX, R = CO2Me) (X), which was transformed to IX (R = CONHNH2) on heating with hydrazine. Monosulfide (V, R = CO2Me), disulfide X, and trisulfide XI were obtained from the reaction of I with sulfur monochloride. Reaction of 1-methylindole-2-carboxylic acid hydrazide with sulfuryl chloride led to the dichloro compound (XII), and I with sulfuryl chloride afforded the tetrachloro compound (XIII) and the hexachloro compound (XIV).

IT 92109-30-3, Indole-2-carboxylic acid, 3-(dimethylsulfamoyl)-1-methyl-, methyl ester
(preparation of)

RN 92109-30-3 CAPLUS
CN Indole-2-carboxylic acid, 3-(dimethylsulfamoyl)-1-methyl-, methyl ester (7CI) (CA INDEX NAME)



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
furanylmethyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 287725-47-7 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-[[bis(2-methoxyethyl)amino]sulfonyl]-1-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 287725-49-9 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[[(2-hydroxyphenyl)methyl]methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.79	182.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

STN INTERNATIONAL LOGOFF AT 14:56:54 ON 21 APR 2006